SYSTEM PROBLEMS:
We are currently experiencing technical problems with content and functionality requiring a login.
We apologize for the inconvience.
Showing session: reset
NEW DRUGS, OLD DRUGS, AND NEW RESISTANCE MECHANISMS
- Sort by:
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
7 of
7
|
STRUCTURAL BASIS FOR VIRAL RESISTANCE TO LONG-ACTING HIV-1 CAPSID INHIBITOR GS-6207 (ABSTRACT
420)
Stephanie Marie Bester
University of Colorado Anschutz Medical Campus, Aurora, CO, USA
GSK3640254 IS A NOVEL MATURATION INHIBITOR WITH AN OPTIMIZED VIROLOGY PROFILE (ABSTRACT
421)
Jerry L Jeffrey
ViiV Healthcare, Research Triangle Park, NC, USA
REDUCED SUSCEPTIBILITY TO TEMSAVIR IS NOT LINKED TO IBA OR MVC RESISTANCE (ABSTRACT
422)
Mark Krystal
ViiV Healthcare, Branford, CT, USA
HIV-1 5'-LEADER MUTATIONS IN PWH DEVELOPING RTI-RESISTANCE MUTATIONS (ABSTRACT
423)
Janin Nouhin
Stanford University, Palo Alto, CA, USA
MUTATIONS IN GP41 IN PRIMARY HIV-1 ISOLATES CONFER RESISTANCE TO ANTIRETROVIRALS (ABSTRACT
424)
Yuta Hikichi
National Cancer Institute, Frederick, MD, USA
EVALUATION OF BNAB SENSITIVITY BY GENOTYPING AND PHENOTYPING FOR HIV CLINICAL TRIALS (ABSTRACT
425)
Brian Moldt
Gilead Sciences, Inc, Foster City, CA, USA
VARIANT SELECTION, CHARACTERIZATION, AND IMPACT ON ANTIBODY SARS-COV-2 NEUTRALIZATION (ABSTRACT
426)
Nicole Kallewaard
Eli Lilly and Company, Indianapolis, IN, USA
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
7 of
7
|
